Therefore, it is probably reasonable to routinely prefer new ADP receptor blockers over clopidogrel in T2D patients in order to ensure more effective platelet inhibition and prevent these serious thrombotic adverse events. The gene discussed is P2RY1; the disease is type 2 diabetes mellitus.